95 related articles for article (PubMed ID: 9879344)
1. Clinical trial experience using erythropoietin during radiation therapy.
Lavey RS
Strahlenther Onkol; 1998 Dec; 174 Suppl 4():24-30. PubMed ID: 9879344
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
3. rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K; Gascón P; Sigounas G; Jolliffe L
Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy.
Massa E; Madeddu C; Lusso MR; Gramignano G; Mantovani G
Crit Rev Oncol Hematol; 2006 Feb; 57(2):175-82. PubMed ID: 16213740
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
Baron F; Frère P; Fillet G; Beguin Y
Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
[TBL] [Abstract][Full Text] [Related]
6. rHuEPO and treatment outcomes: the preclinical experience.
Ludwig H
Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study.
Lavey RS; Liu PY; Greer BE; Robinson WR; Chang PC; Wynn RB; Conrad ME; Jiang C; Markman M; Alberts DS
Gynecol Oncol; 2004 Oct; 95(1):145-51. PubMed ID: 15385124
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
9. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
10. The causes and prognostic significance of low hemoglobin levels in tumor patients.
Manegold C
Strahlenther Onkol; 1998 Dec; 174 Suppl 4():17-9. PubMed ID: 9879342
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
12. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
Vanstraelen G; Baron F; Willems E; Bonnet C; Hafraoui K; Frère P; Fillet G; Beguin Y
Exp Hematol; 2006 Jul; 34(7):841-50. PubMed ID: 16797411
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
Crawford J
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).
Machtay M; Pajak TF; Suntharalingam M; Shenouda G; Hershock D; Stripp DC; Cmelak AJ; Schulsinger A; Fu KK;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1008-17. PubMed ID: 17716826
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
[TBL] [Abstract][Full Text] [Related]
17. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin.
Wun T; Law L; Harvey D; Sieracki B; Scudder SA; Ryu JK
Cancer; 2003 Oct; 98(7):1514-20. PubMed ID: 14508840
[TBL] [Abstract][Full Text] [Related]
18. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
19. Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors.
Steinmetz T; Hellmich M; Neise M; Aldaud A; Lerchenmüller C; Tsamaloukas A; Fandel F; Weiligmann C; Totzke U; Schmitz S
Oncologist; 2007 Jun; 12(6):748-55. PubMed ID: 17602064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
